Parkinson's Disease Clinic and Research Center

Study Title:

Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease

This Phase 2 clinical study delivers neurturin (NTN), a protein related to glial cell line-derived neurotrophic factor (GDNF), to both the putamen and substantia nigra. Patients are randomized to either the treatment versus sham surgery. 

Eligibility:

1. Moderate to advanced Parkinson's disease
2. Both sides affected, classic PD with motor fluctuations
3. Good postural stability in the “on” state
4. Age 35-70 years
5. Normal cognitive status

Contact:

Robin Taylor

robin.taylor@ucsf.edu

(415) 353-1555

For more information, please visit the study page at clinicaltrials.gov, here.